CPSE:NOVO BPharmaceuticals
Novo Nordisk Deepens Cell Therapy Bet With Aspect Diabetes Partnership
Novo Nordisk (CPSE:NOVO B) has expanded its partnership with Canadian biotech Aspect Biosystems to develop advanced cell based therapies for diabetes.
The deal deepens Novo Nordisk's push into off the shelf cellular medicines that aim for disease modifying and potentially curative treatment options.
Aspect Biosystems gains rights to key stem cell and hypoimmune technologies, while Novo Nordisk increases investment and keeps future commercialisation options.
The partnership integrates Novo...